Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. (SHA:603168)
China · Delayed Price · Currency is CNY 7.42
+0.10 (1.37%)
Feb 4, 2026, 3:00 PM CST
SHA:603168 Revenue
Zhejiang Shapuaisi Pharmaceutical had revenue of 114.54M CNY in the quarter ending September 30, 2025, a decrease of -6.54%. This brings the company's revenue in the last twelve months to 475.19M, down -6.01% year-over-year. In the year 2024, Zhejiang Shapuaisi Pharmaceutical had annual revenue of 483.96M, down -24.96%.
Revenue (ttm)
475.19M
Revenue Growth
-6.01%
P/S Ratio
5.76
Revenue / Employee
357.82K
Employees
1,328
Market Cap
2.74B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 483.96M | -161.01M | -24.96% |
| Dec 31, 2023 | 644.97M | 95.43M | 17.37% |
| Dec 31, 2022 | 549.54M | -80.23M | -12.74% |
| Dec 31, 2021 | 629.76M | 282.96M | 81.59% |
| Dec 31, 2020 | 346.81M | -169.15M | -32.78% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Anhui Fengyuan Pharmaceutical | 4.15B |
| Guizhou Yibai Pharmaceutical | 1.91B |
| Hainan Huluwa Pharmaceutical Group | 1.06B |
| Enwei Pharmaceutical | 888.64M |
| ShanXi C&Y Pharmaceutical Group Co.,LTD. | 849.26M |
| Chengdu huasun technology group Inc. , LTD. | 658.28M |
| Ginwa Enterprise (Group) | 550.44M |
| Anhui Huangshan Capsule | 471.08M |